Agios Pharmaceuticals, Inc.(AGIO)Earnings, Financials & Key RatiosAgios Pharmaceuticals, Inc. (AGIO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's precarious liquidity position, evidenced by a cash balance of only $113.6 million against quarterly operating losses of $110 million, suggests an imminent risk of further shareholder dilution.
Agios Pharmaceuticals, Inc. (AGIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Agios Pharmaceuticals, Inc. (AGIO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $1.69vs $1.81+6.6% | $21Mvs $13M+56.0% |
| Q1 2026 | Feb 12, 2026 | $1.85vs $1.97+6.1% | $20Mvs $12M+65.1% |
| Q4 2025 | Oct 30, 2025 | $1.78vs $1.93+7.8% | $13Mvs $12M+10.1% |
| Q3 2025 | Jul 31, 2025 | $1.93vs $1.74-10.9% | $12Mvs $10M+21.2% |
Recent stock market news and headlines for Agios Pharmaceuticals, Inc. (AGIO)
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m.
Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new ITP rights add to its rare blood disease push.
Key metrics vs top competitors for Agios Pharmaceuticals, Inc. (AGIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $44.01 | $2.62B | -6.18 | 48.03% | -764.01% | -30.2% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
Agios Pharmaceuticals, Inc. (AGIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Agios Pharmaceuticals, Inc. (AGIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 29, 2026·SEC
Feb 12, 2026·SEC
Jan 12, 2026·SEC
Get notified when AGIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Agios Pharmaceuticals, Inc. (AGIO) stock FAQ — growth, dividends, profitability & financials explained
Agios Pharmaceuticals, Inc. (AGIO) reported $66.0M in revenue for fiscal year 2025. This represents a 202% increase from $21.8M in 2011.
Agios Pharmaceuticals, Inc. (AGIO) grew revenue by 48.0% over the past year. This is strong growth.
Agios Pharmaceuticals, Inc. (AGIO) reported a net loss of $422.6M for fiscal year 2025.
Agios Pharmaceuticals, Inc. (AGIO) has a return on equity (ROE) of -30.2%. Negative ROE indicates the company is unprofitable.
Agios Pharmaceuticals, Inc. (AGIO) had negative free cash flow of $384.7M in fiscal year 2025, likely due to heavy capital investments.
